Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in Triple-Negative Breast Tumors
2009-015238-31Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide, doxorubicin, docetaxel, capecitabine, thiotepa and 2 more in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Primary endpoint (HRD tumors). Started Oct 2009; status: active.
02
Drugs
cyclophosphamidedoxorubicindocetaxelcapecitabinethiotepa
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2009-015238-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015238-31.